ONO PHARMACEUTICAL CO.,LTD. [4528.T]
TOKYO, May 08 (Pulse News Wire) – ONO Pharmaceutical CO.,LTD. (4528.T) reported consolidated revenue of ¥4,556 billion for the fiscal year ending March 2026, marking a 5.78% increase compared to the previous year.
While domestic product sales declined due to increased competition and entry of generics, overseas sales saw growth driven by products such as KINLOK and LONBRIZMA. Core operating profit reached ¥256 billion, up 21.09%, primarily due to cost efficiencies and higher royalty income. Domestic product sales were negatively impacted by a decline in key drugs like OPDIVO and FOSIGA, which faced intense competition and generic entries. However, overseas sales grew significantly, particularly through the strong performance of KINLOK and LONBRIZMA.
Royalty income also contributed positively, increasing by 13.2%. Looking ahead, the company expects consolidated revenue to decrease by 6.88% in the next fiscal year, mainly due to anticipated reductions in product sales following the end of certain joint ventures. Core operating profit is projected to drop by 17.3%, reflecting lower expected revenues and reduced research and development expenses. Despite these challenges, ONO remains committed to advancing its pipeline of innovative treatments, including several promising candidates currently in various stages of clinical trials.
🟢 Confidence: High AI-translated content.